1. Home
  2. GSIW vs TIL Comparison

GSIW vs TIL Comparison

Compare GSIW & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

N/A

Current Price

$16.90

Market Cap

42.6M

Sector

N/A

ML Signal

N/A

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

N/A

Current Price

$7.58

Market Cap

48.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSIW
TIL
Founded
2016
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.6M
48.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
GSIW
TIL
Price
$16.90
$7.58
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$125.00
AVG Volume (30 Days)
6.7K
6.4K
Earning Date
08-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$5.67
52 Week High
$38.55
$33.83

Technical Indicators

Market Signals
Indicator
GSIW
TIL
Relative Strength Index (RSI) 37.65 N/A
Support Level $15.24 N/A
Resistance Level $20.00 N/A
Average True Range (ATR) 1.66 0.00
MACD 0.22 0.00
Stochastic Oscillator 51.56 0.00

Price Performance

Historical Comparison
GSIW
TIL

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: